Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Inflammatory Vascular Disease

  • Chapter
Retinal Vascular Disease

Abstract

Henry Eales, a British ophthalmologist, described this condition almost 125 years ago [14, 15]. Eales’ original description was of recurring retinal and vitreous hemorrhages along with epistaxis, headaches, variation in peripheral circulation, dyspepsia, and chronic constipation in young men. He felt it was a vasomotor neurosis, wherein constriction of the alimentary vessels resulted in compensatory dilatation of the vessels in the head, leading to bleeding. Though Eales was honored with the eponym for this disease, Wadsworth was the first to describe the presence of retinal inflammation, 5 years later [37]. Duke Elder considered Eales’ disease to be a clinical manifestation of many diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Badrinath SS, Gopal L, Sharma T et al (1999) Vitreoschisis in Eales’ disease: pathogenic role and significance in surgery. Retina 19:51–54

    PubMed  CAS  Google Scholar 

  2. Bali T, Saxena S, Kumar D (2005) Response time and safety profile of pulsed oral methotrexate therapy in idiopathic retinal periphlebitis. Eur J Ophthalmol 15:374–378

    PubMed  CAS  Google Scholar 

  3. Biswas J, Badrinath SS (1995/1996) Ocular morbidity in patients with active systemic tuberculosis. Int Ophthalmol 19:293–298

    PubMed  Google Scholar 

  4. Biswas J, Rao NA (1990) Epiretinal membrane in Eales’ disease and other vascular retinopathies. Invest Ophthalmol Vis Sci 31[Suppl]:369

    Google Scholar 

  5. Biswas J, Narain S, Roy S, Madhavan HN (1997) Evaluation of lymphocyte proliferation assay to purified protein derivative, enzyme-linked immunosorbent assay and tuberculin hypersensitivity in Eales’ disease. India J Ophthalmol 45: 93–97

    CAS  Google Scholar 

  6. Biswas J, Mukesh BN, Narain S, Roy S, Madhavan HN (1998) Profiling of human leukocyte antigen in Eales’ disease. Int Ophthalmol 21:277–281

    CAS  Google Scholar 

  7. Biswas J, Raghavendran R et al (2001) Presumed Eales disease with neurologic involvement: report of three cases. Retina 21:141–145

    PubMed  CAS  Google Scholar 

  8. Biswas J, Sharma T, Gopal L, Madhavan HN, Sulochana KN, Ramakrishnan S (2002) Eales disease-an update. Surv Ophthalmol 47:197–214

    PubMed  Google Scholar 

  9. Charmis J (1965) On the classification and management of the evolutionary course of Eales’ disease. Trans Ophthalmol Soc UK 85:187

    Google Scholar 

  10. Das T, Biswas J, Kumar A, Nagpal PN, Namperumalsamy P et al (1994) Eales’ disease. Indian J Ophthalmol 42:3–18

    PubMed  CAS  Google Scholar 

  11. Das TP, Namperumalsamy P (1987) Combined photocoagulation and cryotherapy in treatment of Eales’ retinopathy. Proc All Ind Ophthalmol Soc 45:108

    Google Scholar 

  12. Das TP, Namperumalsamy P (1990) Photocoagulation in Eales’ disease. Results of prospective randomised clinical study. Presented in XXVI Int Cong Ophthalmol, Singapore

    Google Scholar 

  13. Duke-Elder S, Dobree JH (1967) System of ophthalmology, vol X. Kimpton, London

    Google Scholar 

  14. Eales H (1880) Retinal haemorrhages associated with epistaxis and constipation. Brim Med Rev 9:262

    Google Scholar 

  15. Eales H (1882) Primary retinal haemorrhage in young men. Ophthalmic Rev 1:41

    Google Scholar 

  16. Elliot AJ (1975) Thirty years observation of patients with Eales’ disease. Am J Ophthalmol 80:404

    PubMed  CAS  Google Scholar 

  17. Gadkari SS, Kamdar P, Jehangir RP (1992) Pars plana Vitrectomy in Vitreous haemorrhage due to Eales’ disease. Ind J Ophthalmol 40:35–37

    CAS  Google Scholar 

  18. Gopal L, Abraham C (1985) Efficacy of photocoagulation in Eales’ disease. Trans Asia-pacific. Acad Ophthalmol 10:689

    Google Scholar 

  19. Gunisha P, Madhavan HN, Jayanthi U, Therese KL (2000) Polymerase chain reaction using IS6110 primer to detect Mycobacterium tuberculosis in clinical samples. Indian J Path Microbiol 43:395–402

    CAS  Google Scholar 

  20. Kalsi R, Patnaik B (1979) The developing features of phlebitis retinae (a vertical study). Ind J Ophthalmol 27:87

    Google Scholar 

  21. Madhavan, HN. Therese KL, Gunisha P, Jayanthi U, Biswas J (2000) Polymerase chain reaction for detection of Mycobacterium tuberculosis in epiretinal membrane in Eales’ disease. Invest Ophthalmol Vis Sci 41:822–825

    PubMed  CAS  Google Scholar 

  22. Madhavan HN, Therese KL, Dora Swamy K (2002) Further investigations on two association of Mycobacterium Tuberculosis with Eales disease. Ind J Ophthalmol 50:35–39

    Google Scholar 

  23. Majji AB, Vemuganti GK, Shah VA et al (2006) A comparative study of epiretinal membranes associated with Eales’ disease: a clinicopathologic evaluation. Eye 20:46–54

    PubMed  CAS  Google Scholar 

  24. Malik SRK, Patnaik B (1973) Fluorescein angiography in Eales’ disease. Ind J Ophthalmol 21:5

    CAS  Google Scholar 

  25. Masson C, Denis P, Prier S et al (1988) Eales’ disease with neurologic disorders. Fre Revue Neulogeque 144:817–819

    CAS  Google Scholar 

  26. Murthy KR, Abrabam C, Baig SM et al (1977) Eales’ disease. Proc All Ind Ophthalmol Soc 33:323

    Google Scholar 

  27. Murphy RP, Renie WA, Proctor LR, Shimuzu H, Lippmann SM, Anderson KC, Fine SL, Patz A, McKusick VA (1983) A survey of patients with Eales’ disease. In: Fine SL, Owen SL (eds) Management of retinal vascular and macular disorders. Williams and Wilkin, Baltimore MD

    Google Scholar 

  28. Namperumalsamy P, Kelkar AR, Das TP (1990) Vitreous surgery in Eales’ disease-when and why presented in XXVI Ophthalmol, Singapore

    Google Scholar 

  29. Patnaik B, Kalsi R, Chary P (1980) Cryopexy in the management of diabetic retinopathy. Preliminary report. Proc All Ind Ophthalmol Soc 39:197

    Google Scholar 

  30. Rajesh M, Sulochana KN et al (2004) Determination of carbonyl group content in plasma proteins as a useful marker to assess impairment in antioxidant defense in patients with Eales’ disease. Indian J Ophthalmol 52:139–144

    PubMed  Google Scholar 

  31. Renie WA, Murphy RP, Anderson KC et al (1983) The evaluation of patients with Eales’ disease. Retina 3:243–248

    PubMed  CAS  Google Scholar 

  32. Saxena S, Kumar D (2004) A new staging system for idiopathic retinal periphlebitis. Eur J Ophthalmol 14:236–239

    PubMed  CAS  Google Scholar 

  33. Shanmugam MP, Badrinath SS, Gopal L, Sharma T (1998) Long term visual results of vitrectomy for Eales’ disease complications. Int Ophthalmol 22:61–64

    PubMed  CAS  Google Scholar 

  34. Singhal BS, Dastur DK (1976) Eales’ disease with neurological involvement. Part I. Clinical Features in 9 patients. J Neurol Sci 27:313–321

    PubMed  CAS  Google Scholar 

  35. Spitzans M, Meyer-Schwickerath GT, Stephen B (1975) Clinical Picture of Eales’ disease. Graefes Arch Clin Exp Ophthalmol 194:73

    Google Scholar 

  36. Theodosisadis G (1970) Fluorescein angiography in Eales’ disease. Am J Ophthalmol 69:271

    Google Scholar 

  37. Wadsworth OF (1887) Recurrent retinal haemorrhage followed by the development of blood vessels in the vitreous. Ophthalmic Rev 6:289

    Google Scholar 

References

  1. Accinni L, Dixon FJ (1979) Degenerative vascular disease and myocardial infarction in mice with lupus-like syndrome. Am J Pathol 96:477–492

    PubMed  CAS  Google Scholar 

  2. Anolik JH, Aringer M (2005) New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 19:859–878

    PubMed  CAS  Google Scholar 

  3. Arevalo JF, Lowder CY, Muci-Mendoza R (2002) Ocular manifestations of systemic lupus erythematosus. Curr Opin Ophthalmol 13:404–410

    PubMed  Google Scholar 

  4. Aronson AJ, Ordonez NG, Diddie KR, Ernest JT (1979) Immune-complex deposition in the eye in systemic lupus erythematosus. Arch Intern Med 139:1312–1313

    PubMed  CAS  Google Scholar 

  5. Asherson RA, Merry P, Acheson JF, Harris EN, Hughes GR (1989) Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the ‘primary’ antiphospholipid syndrome. Ann Rheum Dis 48:358–361

    PubMed  CAS  Google Scholar 

  6. Benucci M, Del Rosso A, Li Gobbi F, Manfredi M, Cerinic MM, Salvarani C (2005) Systemic lupus erythematosus (SLE) in Italy: an Italian prevalence study based on a two-step strategy in an area of Florence (Scandicci-Le Signe). Med Sci Monit 11:CR420–CR425

    PubMed  Google Scholar 

  7. Boumpas DT, Austin HA 3rd, Fessler BJ, Balow JE, Klippel JH, Lockshin MD (1995a) Systemic lupus erythematosus: emerging concepts, part 1. Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med 122:940–950

    PubMed  CAS  Google Scholar 

  8. Boumpas DT, Fessler BJ, Austin HA 3rd, Balow JE, Klippel JH, Lockshin MD (1995b) Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 123:42–53

    PubMed  CAS  Google Scholar 

  9. Cobo-Soriano R, Sanchez-Ramon S, Aparicio MJ, Teijeiro MA, Vidal P, Suarez-Leoz M, Rodriguez-Mahou M, Rodriguez-Huerta A, Fernandez-Cruz E, Cortes C (1999) Antiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. Am J Ophthalmol 128:725–732

    PubMed  CAS  Google Scholar 

  10. Cordes FC, Aiken SD (1947) Ocular changes in acute disseminated lupus erythematosus; report of a case with microscopic changes. Am J Ophthalmol 30:1541–1555

    Google Scholar 

  11. Galindo-Rodriguez G, Avina-Zubieta JA, Pizarro S, Diaz de Leon V, Saucedo N, Fuentes M, Lavalle C (1999) Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial. Am J Med 106:65–69

    Google Scholar 

  12. Gold DH, Morris DA, Henkind P (1972) Ocular findings in systemic lupus erythematosus. Br J Ophthalmol 56:800–804

    PubMed  CAS  Google Scholar 

  13. Gourley MF, Austin HA 3rd, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125:549–557

    PubMed  CAS  Google Scholar 

  14. Graham EM, Spalton DJ, Barnard RO, Garner A, Russel RWR (1985) Cerebral and retinal vascular changes in systemic lupus erythematosus. Ophthalmology 92: 44–448

    Google Scholar 

  15. Griffiths B, Mosca M, Gordon C (2005) Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol 19:685–708

    PubMed  Google Scholar 

  16. Hahn BH (1997) Systemic lupus erythematosus. In: Harrison TR et al (eds) Harrison’s principles of internal medicine. McGraw Hill, New York, pp 1874–1880

    Google Scholar 

  17. Hochberg MC, Boyd RE, Ahearn JM, Arnett FC, Bias WB, Provost TT, Stevens MB (1985) Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore) 64:285–295

    CAS  Google Scholar 

  18. Hochberg MC, Perlmutter DL, Medsger TA, Steen V, Weisman MH, White B, Wigley FM (1995) Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA. Lupus 4:454–456

    PubMed  CAS  Google Scholar 

  19. Jabs DA, Fine SL, Hochberg MC, Newman SA et al (1986a) Severe retinal vaso-occlusive disease in systemic lupus erythematosus. Arch Ophthalmol 104:558–563

    PubMed  CAS  Google Scholar 

  20. Jabs DA, Miller NR, Newman SA (1986b) Optic neuropathy in systemic lupus erythematosus. Arch Ophthalmol 104: 564–568

    PubMed  CAS  Google Scholar 

  21. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192

    PubMed  CAS  Google Scholar 

  22. Karlson EW, Daltroy LH, Lew RA, Wright EA, Partridge AJ, Fossel AH, Roberts WN, Stern SH, Straaton KV, Wacholtz MC, Kavanaugh AF, Grosflam JM, Liang MH (1997) The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 40:47–56

    PubMed  CAS  Google Scholar 

  23. Karpik AG, Schwartz MM, Dickey LE, Streeten BW, Roberts JL (1985) Ocular immune reactants in patients dying with systemic lupus erythematosus. Clin Immunol Immunopathol 35:295–312

    PubMed  CAS  Google Scholar 

  24. Lorenz HM, Grunke M, Wendler J, Heinzel PA, Kalden JR (2005) Safety of 15-deoxyspergualin in the treatment of glomerulonephritis associated with active systemic lupus erythematosus. Ann Rheum Dis 64:1517–1519

    PubMed  Google Scholar 

  25. Marmor MF (2003) New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis Rheum 48:1764

    PubMed  Google Scholar 

  26. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF (2002) Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 109: 1377–1382

    PubMed  Google Scholar 

  27. Meister P (2003) Vasculitides: classification, clinical aspects and pathology. A review. Pathologe 24:165–181

    PubMed  Google Scholar 

  28. Montehermoso A, Cervera R, Font J, Ramos-Casals M, Garcia-carrasco M, Formiga F, Callejas JL, Jorfan M, Grino MC, Ingelmo M (1999) Association of antiphospholipid antibodies with retinal vascular disease in systemic lupus erythematosus. Semin Arthritis Rheum 28:326–332

    PubMed  CAS  Google Scholar 

  29. Nag TC, Wadhwa S (2005) Histopathological changes in the eyes in systemic lupus erythematosus: an electron microscope and immunohistochemical study. Histol Histopathol 20:373–382

    PubMed  CAS  Google Scholar 

  30. Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M (1991) Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 91:345–353

    PubMed  CAS  Google Scholar 

  31. Ramal LM, Lopez-Nevot MA, Sabio JM, Jaimez L, Paco L, Sanchez J, de Ramon E, Fernandez-Nebro A, Ortego N, Ruiz-Cantero A, Rivera F, Martin J, Jimenez-Alonso J (2004) Systemic lupus erythematosus in southern Spain: a comparative clinical and genetic study between Caucasian and Gypsy patients. Lupus 13:934–940

    PubMed  CAS  Google Scholar 

  32. Riemekasten G, Hahn BH (2005) Key autoantigens in SLE. Rheumatology (Oxf) 44:975–982

    CAS  Google Scholar 

  33. Rosenbaum JT, Robertson JE Jr, Watzke RC (1991) Retinal vasculitis-a primer. West J Med 154:182–185

    PubMed  CAS  Google Scholar 

  34. Rosenbaum JT, Simpson J, Neuwelt CM (1997) Successful treatment of optic neuritis in association with systemic lupus erythematosus using intravenous cyclophosphamide. Br J Ophthalmol 81:130–132

    PubMed  CAS  Google Scholar 

  35. Rosenbaum JT, Wernick R (1990) The utility of routine screening of patients with uveitis for systemic lupus erythematosus or tuberculosis. A Bayesian analysis. Arch Ophthalmol 108:1291–1293

    PubMed  CAS  Google Scholar 

  36. Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR (2001) Systemic lupus erythematosus. Lancet 357:1027–1032

    PubMed  CAS  Google Scholar 

  37. Soo MP, Chow SK, Tan CT, Nadior N, Yeap SS, Hoh HB (2000) The spectrum of ocular involvement in patients with systemic lupus erythematosus without ocular symptoms. Lupus 9:511–514

    PubMed  CAS  Google Scholar 

  38. Stafford-Brady FJ, Urowitz MB, Gladman DD, Easterbrook M (1988) Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum 31:1105–1110

    PubMed  CAS  Google Scholar 

  39. Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G (2000) Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 27: 685–691

    PubMed  CAS  Google Scholar 

  40. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277

    PubMed  CAS  Google Scholar 

  41. Tuft SJ, Watson PG (1991) Progression of scleral disease. Ophthalmology 98:467–471

    PubMed  CAS  Google Scholar 

  42. Zimmerman R, Radhakrishnan J, Valeri A, Appel G (2001) Advances in the treatment of lupus nephritis. Annu Rev Med 52:63–78

    PubMed  CAS  Google Scholar 

References

  1. Accorinti M, Pirraglia MP, Corradi R, Marino M, Pivetti-Pezzi P (2003) Ocular lesions other than Behcet’s disease in Behcet’s disease-affected patients. In: Zouboulis CC (ed) Adamantiades-Behcet’s disease. Kluwer Academic/Plenum Publishers, New York, pp 365–368

    Google Scholar 

  2. Adler YD, Mansmann U, Zouboulis CC (2001) Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet’s disease. Dermatology 203:322–324

    PubMed  CAS  Google Scholar 

  3. Ambresin A, Tran T, Spertini F, Herbort C (2002) Behçet’s disease in Western Switzerland: Epidemiology and analysis of ocular involvement. Ocul Immunol Inflamm 10:53–63

    PubMed  CAS  Google Scholar 

  4. Ates A, Kinikli G, Duzgun N, Duman M(2006) Lack of association of tumor necrosis factor-alpha gene polymorphisms with disease susceptibility and severity in Behçet’s disease. Rheumatol Int 26:348–353

    PubMed  CAS  Google Scholar 

  5. Atmaca LS, Batioglu F, Müftüoglu O (2003) Fluorescein Angiography and optical Coherence Tomography in ocular Behcet’s disease. In: Zouboulis CC (ed) Adamantiades-Behcet’s disease. Kluwer Academic/Plenum Publishers, New York, pp 355–360

    Google Scholar 

  6. Ayaslioglu E, Duzgun N, Erkek E, Inal A (2004) Evidence of chronic Chlamydia pneumoniae infection in patients with Behcet’s disease. Scand J Infect Dis 36:428–430

    PubMed  Google Scholar 

  7. Aydintug AO, Tokgöz G, D’Cruz DP, Gürler A, Cervera R, Düzgün N, Atmaca LS, Khamashta MA, Hughes GR (1993) Antibodies to endothelial cells in patients with Behçet’s disease. Clin Immunol Immunopathol 67:157–162

    PubMed  CAS  Google Scholar 

  8. BenEzra D, Cohen E (1986) Treatment and visual prognosis in Behçet’s disease. Br J Ophthalmol 70:589–592

    PubMed  CAS  Google Scholar 

  9. Berlit P, Stueper B, Fink I, Rebmann V, Hoyer P, Kreuzfelder E, Grosse-Wilde H (2005) Behçet’s disease is associated with increased concentrations of antibodies against phosphatidylserine and ribosomal phosphoproteins. Vasa 34: 176–180

    PubMed  CAS  Google Scholar 

  10. Boiardi L, Salvarani C, Casali B, Olivieri I, Ciancio G, Cantini F, Salvi F, Malatesta R, Govoni M, Trotta F, Filippini D, Paolazzi G, Nicoli D, Farnetti E, Macchioni L (2001) Intercellular adhesion molecule-1 gene polymorphisms in BD. J Rheumatol 28:1283–1287

    PubMed  CAS  Google Scholar 

  11. Carletto A, Pacor ML, Biasi D, Caramaschi P, Zeminian S, Bellavite P, Bambara LM (1997) Changes of neutrophil migration without modification of in vitro metabolism and adhesion in Behçet’s disease. J Rheumatol 24:1332–1336

    PubMed  CAS  Google Scholar 

  12. Cervera R, Navarro M, Lopez-Soto A, Cid MC, Font J, Esparza J, Reverter JC, Monteagudo J, Ingelmo M, Urbano-Marquez A (1994) Antibodies to endothelial cells in BD: cell-binding heterogeneity and association with clinical activity. Ann Rheum Dis 53:265–267

    PubMed  CAS  Google Scholar 

  13. Chafa O, Fischer AM, Meriane F, Chellali T, Sternberg C, Otmani F, Benabadji M (1992) Behçet syndrome associated with protein S deficiency. Thromb Haemost 67:1–3

    PubMed  CAS  Google Scholar 

  14. Chajek T, Fainaru M (1975) Behcet’s disease: Report of 41 cases and a review of the literature. Medicine 54:179–196

    PubMed  CAS  Google Scholar 

  15. Chambers JC, Haskard DO, Kooner JS (2001) Vascular endothelial function and oxidative stress mechanisms in patients with Behçet’s syndrome. J Am Coll Cardiol 37: 517–520

    PubMed  CAS  Google Scholar 

  16. Cochereau-Massin I, Wechsler B, Le Hoang P, Huong LeThi D, Girard B, Rousselie F (1992) Ocular prognosis in Behçet’s disease. J Fr Ophthalmol 15:343–347

    Google Scholar 

  17. Davatchi F (2003) Treatment of ocular manifestations of Behcet’s disease. Adv Exp Med Biol 528:487–491

    PubMed  CAS  Google Scholar 

  18. Deuter CME, Zierhut M (2006) Interferons for intraocular inflammation. Ophthalmol Int (in press)

    Google Scholar 

  19. Deuter CME, Kötter I, Günaydin I, Zierhut M, Stübiger N (2004) Ocular involvement in Behçet’s disease: first 5-year results for visual development after treatment with interferon alpha-2a. Ophthalmologe 101:129–134

    PubMed  CAS  Google Scholar 

  20. Dilsen N, Konice M, Aral O, Ocal L, Inanc M, Gul A (1993) Comparative study of the skin pathergy test with blunt and sharp needles in BD: confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis 52:823–825

    PubMed  CAS  Google Scholar 

  21. Direskeneli H, Keser G, D’Cruz D, Khamashta MA, Akoglu T, Yazici H, Yurdakul S (1995) Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behçet’s disease. Clin Rheumatol 14:55–61

    PubMed  CAS  Google Scholar 

  22. Donmez A, Aksu K, Celik HA, Keser G Cagirgan S, Omay SB, Inal V Aydin HH, Tombuloglu M, Doganavsargil E (2005) Thrombin activatable fibrinolysis inhibitor in Behçet’s disease. Thromb Res 115:287–297

    PubMed  CAS  Google Scholar 

  23. Eksioglu-Demiralp E, Direskeneli H, Ergun T, Fresko I, Akoglu T (1999) Increased CD4+CD16+ and CD4+CD56+T cell subsets in Behçet’s disease. Rheumatol Int 19:23–26

    PubMed  CAS  Google Scholar 

  24. Freysdottir J, Farmer I, Lau SH, Hussain L, Verity D, Madanat W et al (1998) Cytokines in BD (P44). 8th International Congress on Behçet’s Disease, Program and Abstracts. Italy, Reggio Emilia, p 143

    Google Scholar 

  25. Giansanti F, Barbera ML, Virgili G, Pieri B, Emmi L, Menchini U (2004) Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behçet disease. Eur J Ophthalmol 14:445–448

    PubMed  CAS  Google Scholar 

  26. Gül A, Esin S, Dilsen N, Konice M, Wigzell H, Biberfeld P (1995) Immunohistology of skin pathergy reaction in BD. Br J Dermatol 132:901–907

    PubMed  Google Scholar 

  27. Gül A, Özbek U, Öztürk C, Inanç M, Koniçe M, Özçelik T (1996) Coagulation factor V gene mutation increases the risk of venous thrombosis in Behçet’s disease. Br J Rheumatol 35:1178–1180

    PubMed  Google Scholar 

  28. Gül A, Aslantas AB, Tekinay T, Koniçe M, Özçelik T (1999) Procoagulant mutations and venous thrombosis in Behçet’s disease. Rheumatology (Oxford) 38:1298–1299

    Google Scholar 

  29. Gül A, Inanc M, Ocal L, Aral O, Konice M (2000) Familial aggregation of BD in Turkey. Ann Rheum Dis 59:622–625

    PubMed  Google Scholar 

  30. Gül A, Hajeer AH, Worthington J, Ollier WE, Silman AJ (2001) Linkage mapping of a novel susceptibility locus for Behçet’s disease to chromosome 6p22-23. Arthritis Rheum 44:2693–2696

    PubMed  Google Scholar 

  31. Gürler A, Boyvat A, Türsen Ü (1997) Clinical manifestations of Behcet’s disease: an analysis of 2147 patients. Yonsei Med J 38:423–427

    PubMed  Google Scholar 

  32. Hamuryudan V, Özyazgan Y, Hizli N, Mat C, Yurdakul S, Tüzün Y, aenocak M, Yazici H (1997) Azathioprine in Behçet’s syndrome: effects on long-term prognosis. Arthritis Rheum 40:769–774

    PubMed  CAS  Google Scholar 

  33. Hasan A, Fortune F, Wilson A, Warr K, Shinnick T, Mizushima Y, van der Zee R, Stanford MR, Sanderson J, Lehner T (1996) Role of γδT cells in pathogenesis and diagnosis of Behçet’s disease. Lancet 347:789–794

    PubMed  CAS  Google Scholar 

  34. Haznedaroglu IC, Dündar SV, Kirazli S (1995) Eicosanoids in the prethrombotic state of Behçet’s disease. Thromb Res 80:445–446

    PubMed  CAS  Google Scholar 

  35. Hu W, Hasan A, Wilson A, Stanford MR, Li-Yang Y, Todryk S, Whiston R, Shinnick T, Mizushima Y, van der Zee R, Lehner T (1998) Experimental mucosal induction of uveitis with 60-kDa heat shock protein-derived peptide 336-351. Eur J Immunol 28:2444–2455

    PubMed  CAS  Google Scholar 

  36. Hughes EH, Collins RW, Kondeatis E, Wallace GR, Graham EM Vaughan RW, Stanford MR (2005) Associations of major histocompatibility complex class I chain-related molecule polymorphisms with Behçet’s disease in Caucasian patients. Tissue Antigens 66:195–199

    PubMed  CAS  Google Scholar 

  37. Ikbal, M, Atasoy M, Pirim I, Aliagaoglu C, Karatay S, Erdem F (2006) The alteration of sister chromatid exchange frequencies in Behçet’s disease with and without HLA-B51. J Eur Acad Dermatol Venereol 20:149–152

    PubMed  CAS  Google Scholar 

  38. Imirzalioglu N, Dursun A, Tastan B, Soysal Y, Yakicier MC (2005) MEFV gene is a probable susceptibility gene for Behçet’s disease. Scand J Rheumatol 34:56–58

    PubMed  CAS  Google Scholar 

  39. International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080

    Google Scholar 

  40. Isogai E, Ohno S, Kotake S, Isogai H, Tsurumizu T, Fujii N, Yokota K, Syuto B, Yamaguchi M, Matsuda H (1990) Chemiluminescence of neutrophils from patients with Behçet’s disease and its correlation with an increased proportion of uncommon serotypes of Streptococcus sanguis in the oral flora. Arch Oral Biol 35:43–48

    PubMed  CAS  Google Scholar 

  41. Itoh Y, Inoko H, Kulski J-K, Sasaki S, Meguro A, Takiyama N, Nishida T, Yuasa T, Ohno S, Mizuki N (2006) Four digit allele genotyping of the HLA-A and HLA-B genes in Japanese patients with Behçet’s disease by a PCR-SSOP-Luminex method. Tissue Antigens 67:390–394

    PubMed  CAS  Google Scholar 

  42. Jang WC, Park SB, Nam YH, Lee SS, Kim JW, Chang IS, Kim KT, Chang HK (2005) Interleukin-18 gene polymorphisms in Korean patients with BD. Clin Exp Rheumatol. 23:59–63

    Google Scholar 

  43. Kaklamani VG, Kaklamanis PG (2001) Treatment of Behçet’s disease-an update. Semin Arthritis Rheum 30:299–312

    PubMed  CAS  Google Scholar 

  44. Kaneko F, Nakamura K, Sato M, Tojo M, Zheng X, Zhang JZ (2003) Epidemiology of Behcet’s disease in Asian countries and Japan. In: Zouboulis CC (ed) Adamantiades-Behcet’s disease. Kluwer Academic/Plenum Publishers, New York, pp 25–29

    Google Scholar 

  45. Kansu E, Sahin G, Sahin F, Sivri B, Sayek I, Batman F (1986) Impaired prostacyclin synthesis by vessel walls in Behçet’s disease. Lancet ii:1554

    Google Scholar 

  46. Karasneh J, Hajeer AH, Barrett J, Ollier WER, Thornhill M, Gul A (2003) Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet’s disease. Rheumatology 42:860–864

    PubMed  CAS  Google Scholar 

  47. Karasneh J, Gul A, Ollier WE, Silman AJ, Worthington J (2005) Whole-genome screening for susceptibility genes in multicase families with Behçet’s disease. Arthritis Rheum 52:1836–1842

    PubMed  CAS  Google Scholar 

  48. Kilmartin DJ, Forrester JV, Dick AD (1998) Tacrolimus (FK506) in failed cyclosporine A therapy in endogenous posterior uveitis. Ocul Immunol Inflamm 6:101–109

    PubMed  CAS  Google Scholar 

  49. Kim JU, Chang HK, Lee SS, Kim JW, Kim KT, Lee SW, Chung WT (2003) Endothelial nitric oxide synthase gene polymorphisms in Behcet’s disease and rheumatic disease with vasculitis. Ann Rheum Dis 62:1083–1087

    PubMed  CAS  Google Scholar 

  50. Kotake S, Higashi K, Yoshikawa K, Sasamoto Y, Okamoto T, Matsuda H (1999) Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology 106:586–589

    PubMed  CAS  Google Scholar 

  51. Kötter I, Zierhut M, Eckstein A, Vonthein R, Ness T, Günaydin I, Grimmbacher P, Blaschke S, Peter HH, Kanz L, Stübiger N (2003) Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behcet’s disease with sight-threatening retinal vasculitis. Br J Ophthalmol 87: 423–431

    PubMed  Google Scholar 

  52. Kötter I, Günaydin I, Zierhut M, Stübiger N (2004) The use of interferon α in Behçet disease: review of the literature. Semin Arthritis Rheum 33:320–335

    PubMed  Google Scholar 

  53. Kretschmann U, Seeliger MW, Ruether K, Usui T, Apfelstedt-Sylla E, Zrenner E (1998) Multifocal electroretinography in patients with Stargardt’s macular dystrophy. Br J Ophthalmol 82:267–275

    PubMed  CAS  Google Scholar 

  54. Lee EB, Kim JY, Lee YJ, Park MH, Song YW (2003a) TNF and TNF receptor polymorphisms in Korean Behçet’s disease patients. Hum Immunol 64:614–620

    PubMed  CAS  Google Scholar 

  55. Lee KH, Bang D, Choi ES, Chun WH, Lee ES, Lee S (1999) Presence of circulating antibodies to a disease-specific antigen on cultured human dermal microvascular endothelial cells in patients with Behçet’s disease. Arch Dermatol Res 291:374–381

    PubMed  CAS  Google Scholar 

  56. Lee KH, Chung HS, Kim HS, Oh SH, Ha MK, Baik JH, Lee S, Bang D (2003b) Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behçet’s disease. Arthritis Rheum 48:2025–2035

    PubMed  CAS  Google Scholar 

  57. Lehner T (1997) The role of heat shock protein, microbial and autoimmune agents in aetiology of Behçet’s disease. Int Rev Immunol 14:21–32

    PubMed  CAS  Google Scholar 

  58. Lehner T (2000) Immunopathogenesis of Behçet’s disease. In: Bang D, Lee ES, Lee S (eds) Behçet’s disease. Design Mecca, Seoul, pp 3–18

    Google Scholar 

  59. Lehner T, Lavery E, Smith R, von der Zee R, Mizushima Y Shinnick T (1991) Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Behçet’s disease. Infect Immun 59:1434–1441

    PubMed  CAS  Google Scholar 

  60. Lu Y, Ye P, Chen SL, Tan EM, Chan EK (2005) Identification of kinectin as a novel Behçet’s disease autoantigen. Arthritis Res Ther 7:R1133–R1139

    PubMed  CAS  Google Scholar 

  61. Mahesh SP, Li Z, Buggage R, Mor F, Cohen IR, Chew EY, Nussenblatt RB (2005) Alpha trompomyosin as a self-antigen in patients with Behçet’s disease. Clin Exp Immunol 140:368–375

    PubMed  CAS  Google Scholar 

  62. Mammo L, Al-Dalaan A, Bahabri SS, Saour JN. (1997) Association of factor V Leiden with Behçet’s disease. J Rheumatol 24:2196–2198

    PubMed  CAS  Google Scholar 

  63. Mamo JG (1970) The rate of visual loss in Behçet’s disease. Arch Ophthalmol 84:451–452

    PubMed  CAS  Google Scholar 

  64. Misgav M, Goldberg Y, Zeltser D, Eldor A, Berliner AS (2000) Fatal pulmonary artery thrombosis in a patient with Behçet’s disease, activated protein C resistance and hyperhomocystinemia. Blood Coagul Fibrinolysis 11:421–423

    PubMed  CAS  Google Scholar 

  65. Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K (1979) The eighth Frederick H. Verhoeff lecture presented by S. Mishima. Behçet’s disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc 77:225–279

    PubMed  CAS  Google Scholar 

  66. Mizuki N, Inoko H, Mizuki N, Tanaka H, Kera J, Tsuiji K, Ohno S (1992) Human leukocyte antigen serologic and DNA typing of Behçet’s disease and its primary association with B51. Invest Ophthalmol Vis Sci 33:3332–3340

    PubMed  CAS  Google Scholar 

  67. Mizuki N, Inoko H, Ohno S (1997) Molecular genetics (HLA) of BD. Yonsei Med J 38:333–349

    PubMed  CAS  Google Scholar 

  68. Müftüoglu AÜ, Yazici H, Yurdakul S, Pazarli H, Ozyazgan Y, Tuzun Y, Altac M, Yalcin B (1981) Behcet’s disease: lack of correlation of clinical manifestations with HLA antigens. Tissue Antigens 17:226–230

    PubMed  Google Scholar 

  69. Musabak U, Baylan O, Cetin T, Yesilova Z, Sengul A, Saglam K, Inal A, Kocar IH (2005) Lipid profile and antivardiolipin antibodies in Behçet’s disease. Arch Med Res 36:387–392

    PubMed  CAS  Google Scholar 

  70. Musabak U, Pay S, Erdem H, Simsek I, Pekel A, Dinc A, Sengul A (2006) Serum interleukin-18 levels in patients with Behçet’s disease. Is its expression associated with disease activity or clinical presentations? Rheumatol Int 26:545–550

    PubMed  CAS  Google Scholar 

  71. Mushtaq B, Saeed T, Situnayake RD, Murray PI (2006) Adalimumab for sight-threatening uveitis in Behçet’s disease. Eye (Epub ahead of print)

    Google Scholar 

  72. Nagafuchi H, Takeno M, Yoshikawa H, Kurokawa MS, Nara K, Takada E, Masuda C, Mizoguchi M, Suzuki N (2005) Excessive expression of Txk, a member of the Tec family of tyrosine kinases, contributes to excessive Th1 cytokine production by T lymphocytes in patients with Behçet’s disease (2005). Clin Exp Immunol 139:363–370

    PubMed  CAS  Google Scholar 

  73. Nakae K, Masaki F, Hashimoto T (1993) Behcet’s disease. In: Wechsler B, Godeau P (eds) International congress series 1037. Excerpta Medica, Amsterdam, pp145–151

    Google Scholar 

  74. Niwa Y, Mizushima Y (1990) Neutrophil-potentiating factors released from stimulated lymphocytes; special reference to the increase in neutrophil-potentiating factors from streptococcus-stimulated lymphocytes of patients with Behçet’s disease. Clin Exp Immunol 79:353–360

    PubMed  CAS  Google Scholar 

  75. Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M (1982) Close association of HLA-Bw51 with Behcet’s disease. Arch Ophthalmol 100:1455–1458

    PubMed  CAS  Google Scholar 

  76. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet’s disease with refractory uveoretinitis. J Rheumatol 31:1362–1368

    PubMed  CAS  Google Scholar 

  77. Okada AA (2000) Drug therapy in Behçet’s disease. Ocul Immunol Inflamm 8:85–91

    PubMed  CAS  Google Scholar 

  78. Özdal PC, Ortac S, Taskintuna I, Firat E (2002a) Posterior segment involvement in ocular Behçet’s disease. Eur J Ophthalmol 12:424–431

    PubMed  Google Scholar 

  79. Özdal PÇ, Ortaç S, Taskintuna I, Firat E (2002b) Long-term therapy with low dose cyclosporine A in ocular Behçet’s disease. Doc Ophthalmol 105:301–312

    PubMed  Google Scholar 

  80. Oztas MO, Onder M, Gurer MA, Bukan N, Sancak B (2005) Serum interleukin 18 an tumor necrosis factor-alpha levels are increased in Behçet’s disease. Clin Exp Dermatol 30:61–63

    PubMed  CAS  Google Scholar 

  81. Ozturk MA, Ertenli I, Kiraz S, C-Haznedaroglu I, Celik I, Kirazli S, Calguneri M (2004) Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of BD. Rheumatol Int 24:98–102

    PubMed  Google Scholar 

  82. Palimeris G, Papakonkonstantinou P, Mantas M (1984) The Adamantiades-Behcet’s syndrome in Greek. In: Saari KM (ed) Uveitis update. Exerpta Medica, Amsterdam

    Google Scholar 

  83. Park KS, Min K, Nam JH, Bang D, Lee ES, Lee S (2005) Association of HYPA haplotype in the nannose-binding lectin gene-2 with Behçet’s disease. Tissue Antigens 65:260–265

    PubMed  CAS  Google Scholar 

  84. Pronai L, Ichikawa Y, Nakzawa H, Arimori S (1991) Enhanced superoxide generation and the decreased scavenging activity of peripheral blood leukocytes in Behçet’s disease-effect of colchicines. Clin Exp Rheumatol 9:227–233

    PubMed  CAS  Google Scholar 

  85. Sakane T, Kotani H, Takada S Tsunematsu T (1982) Functional aberration of T cell subsets in patients with Behçet’s disease. Arthritis Rheum 25:1343–1351

    PubMed  CAS  Google Scholar 

  86. Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet’s disease. N Engl J Med 341:1284–1291

    PubMed  CAS  Google Scholar 

  87. Sallakci N, Bacanli A, Coskun M, Yavuzer U, Alpsoy E, Yegin O (2005) CTLA-4 gene 49A/G polymorphism in Turkish patients with BD. Clin Exp Dermatol 30:546–550

    PubMed  CAS  Google Scholar 

  88. Salvarani C, Calamia K, Silingardi M, Ghirarduzzi A, Olivieri I (2000) Thrombosis associated with the prothrombin GA20210 mutation in Behçet’s disease. J Rheumatol 27: 515–516

    PubMed  CAS  Google Scholar 

  89. Salvarani C, Boiardi L, Casali B, Olivieri I, Ciancio G, Cantini F, Salvi F, Malatesta R, Govoni M, Trotta F, Filippini D, Paolazzi G, Nicoli D, Farnetti E, Macchioni P (2002) Endothelial nitric oxide synthase gene polymorphisms in Behçet’s disease. J Rheumatol 29:535–540

    PubMed  CAS  Google Scholar 

  90. Salvarani C, Boiardi L, Casali B, Olivieri I, Cantini F, Salvi F, Malatesta R, La-Corte R, Triolo G, Ferrante A, Filippini D, Paolazzi G, Sarzi-Puttini P, Nicoli D, Farnetti E, Chen Q, Pulsatelli L (2004) Vascular endothelial growth factor gene polymorphisms in BD J Rheumatol 31:1785–1789

    PubMed  CAS  Google Scholar 

  91. Sari RA, Kiziltunc A, Taysy S, Akdemyr S, Gundoglu M (2005) Levels of soluble E-selectin in patients with active Behçet’s disease. Clin Rheumatol 24:55–59

    PubMed  Google Scholar 

  92. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behçet’s disease. Lancet 358: 295–296

    PubMed  CAS  Google Scholar 

  93. Shehto NM, Ghosh K, Abdul-Kader B, al Assad HS (1992) Extensive venous thrombosis in a case of Behçet’s disease associated with heterozygous protein C deficiency. Thromb Haemost 67:283

    PubMed  CAS  Google Scholar 

  94. Shimizu T, Matsumura N (1972) Behçet’s disease. Nippon Rinsho 30:416–420

    PubMed  CAS  Google Scholar 

  95. Sloper CML, Powell RJ, Dua HS (1999) Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 106:723–728

    PubMed  CAS  Google Scholar 

  96. Stübiger N, Kötter I, Zierhut M (2000) Complete regression of retinal neovascularisation after therapy with interferon alpha in Behçet’s disease. Br J Ophthalmol 84:1437–1438

    Google Scholar 

  97. Stübiger N, Zierhut M, Kötter I (2003) Ocular manifestations in Behçet’s disease. In: Zierhut M, Ohno S (eds) Immunology of Behçet’s disease. Swets and Zeitlinger, Lisse, Tokyo, pp 36–45

    Google Scholar 

  98. Takeno M, Shimoyama Y, Kashiwakura J, Nagafuchi H, Sakane T, Suzuki N (2004) Abnormal killer inhibitory receptor expression on natural killer cells in patients with Behçet’s disease. Rheumatol Int 24:212–216

    PubMed  CAS  Google Scholar 

  99. Takeuchi M, Hokama H, Tsukahara R, Kezuka T, Goto H, Sakai J, Usui M (2005) Risk and prognostic factors of poor visual outcome in Behçet’s disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol 243(11):1147–1152

    PubMed  Google Scholar 

  100. Todaro M, Zerilli M, Triolo G, Iovino F, Patti M, Accardo-Palumbo A, di Gaudio F, Turco MC, Petrella A, de Maria R, Stassi G 2005 (2005) NF-kappaB protects BD T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis Rheum 52:2179–2191

    PubMed  CAS  Google Scholar 

  101. Tokay S, Direskeneli H, Yurdakul S, Akoglu T (2001) Anticardiolipin antibodies in Behçet’s disease: a reassessment. Rheumatology (Oxford) 40:192–195

    PubMed  CAS  Google Scholar 

  102. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, Gül A (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease. Arthritis Rheum 52:2478–2484

    PubMed  CAS  Google Scholar 

  103. Ureten K, Ertenli I, Ozturk MA, Kiraz S, Onat AM, Tuncer M, Okur H, Akdogan A, Apras S, Calguneri M (2005) Neutrophil CD 64 expression in Behçet’s disease. J Rheumatol 32:849–852

    PubMed  CAS  Google Scholar 

  104. Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR (1999a) BD, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 54:213–220

    PubMed  CAS  Google Scholar 

  105. Verity DH, Vaughan RW, Madanat W, Kondeatis E, Zureikat H, Fayyad F, Kanawati CA, Ayesh I, Stanford MR, Wallace GR (1999b) Factor V Leiden mutation is associated with ocular involvement in Behçet’s disease. Am J Ophthalmol 128:352–356

    PubMed  CAS  Google Scholar 

  106. Verjans GM, van Hagen PM, van der Kooi A, Osterhaus AD, Baarsma GS (2002) Vgamma9Vdelta2 T cells recovered from eyes of patients with Behçet’s disease recognize non-peptide prenyl pyrophosphate antigens. J Neuroimmunol 130:46–54

    PubMed  CAS  Google Scholar 

  107. Wakisaka S, Takeba Y, Mihara S, Takeno M, Yamamoto S, Sakane T, Suzuki N (2002) Aberrant Fas ligand expression in lymphocytes in patients with BD. Int Arch Allergy Immunol 129:175–180

    PubMed  CAS  Google Scholar 

  108. Whitcup SM, Salvo EC, Nussenblatt RB (1994) Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet’s disease. Am J Ophthalmol 118: 39–45

    PubMed  CAS  Google Scholar 

  109. Yazici H, Basaran G, Hamuryudan V, Hizli N, Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Dimitriyadis I (1996) The ten-year mortality in Behcet’s syndrome. Br J Rheumatol 35:139–141

    PubMed  CAS  Google Scholar 

  110. Yazici H, Ozyagan Y (1999) Medical management of Behçet’s syndrome. Dev Ophthalmol 31:118–131

    PubMed  CAS  Google Scholar 

  111. Yazici H, Pazarli H, Barnes CG, Tüzün Y, Özyazgan Y, Silman A, Serdaroðlu S, Oðuz V, Yurdakul S, Lovatt GE, Yazici B, Somani S, Müftüoðlu A (1990) A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 322: 281–285

    PubMed  CAS  Google Scholar 

  112. Yurdakul S, Günaydin I, Tuzkun Y, Tankurt N, Pazarli H, Ozyazgan Y, Yasici H (1988) The prevalence of Behcet’s syndrome in a rural area in northern Turkey. J Rheumatol 15:820–822

    PubMed  CAS  Google Scholar 

  113. Zafirakis P, Foster CS (2002) Adamantiades-Behcet’s disease. In: Foster CS, Vitale AT (eds) Diagnosis and treatment of uveitis. Saunders, Philadelphia, pp 632–652

    Google Scholar 

  114. Zierhut M, Mizuki N, Ohno S, Inoko H, Gul A, Onoe K, Isogai E (2003) Immunology and functional genomics of BD. Cell Mol Life Sci 60:1903–1922

    PubMed  CAS  Google Scholar 

  115. Zierhut M, Stübiger N, Deuter CME (2004): Behçet’s disease. In: Pleyer U, Mondino B (eds) Essentials in ophthalmology: uveitis and immunological disorders. Springer, Berlin Heidelberg New York, pp 173–195

    Google Scholar 

  116. Zouboulis CC (1999) Epidemiology of Adamantiades-Behcet’s disease. Ann Med Interne (Paris) 150:488–498

    CAS  Google Scholar 

  117. Zouboulis CC (2003) Epidemiology of Adamantiades-Behcet’s disease. In: Zierhut M, Ohno S (eds) Immunology of Behçet’s disease. Swets and Zeitlinger, Lisse, Tokyo, pp 1–16

    Google Scholar 

  118. Zouboulis CC, Kötter I, Djawari D, Kirch W, Kohl PK, Ochsendorf FR, Keitel W, Stadler R, Wollina Uproksch E, Sohnchen R, Weber H, Gollnick HP, Holzle E, Fritz K, Licht T, Orfanos CE (1997) Epidemiological features of Adamantiades-Behcet’s disease in Germany and in Europe. Yonsei Med J 38:411–422

    Google Scholar 

References

  1. Acar MA, Birch MK, Abbott R, Rosenthal AR (1993) Chronic granulomatous anterior uveitis associated with multiple sclerosis. Graefes Arch Clin Exp Ophthalmol 231(3):166–8

    PubMed  CAS  Google Scholar 

  2. Adamus G, Amundson D, Vainiene M, et al. (1996) Myelin basic protein specific T-helper cells induce experimental anterior uveitis. J Neurosci Res 44(6):513–8

    PubMed  CAS  Google Scholar 

  3. Arnold AC, Pepose JS, Hepler RS, Foos RY (1984) Retinal periphlebitis and retinitis in multiple sclerosis. I. Pathologic characteristics. Ophthalmology 91(3):255–62

    PubMed  CAS  Google Scholar 

  4. Bamford CR, Ganley JP, Sibley WA, Laguna JF (1978) Uveitis, perivenous sheathing and multiple sclerosis. Neurology 28(9):119–24

    PubMed  CAS  Google Scholar 

  5. Beck RW, Chandler DL, Cole SR, et al. (2002) Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 51(4):481–90

    PubMed  CAS  Google Scholar 

  6. Becker MD, Heiligenhaus A, Hudde T, et al. (2005) Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol (in press)

    Google Scholar 

  7. Biousse V, Trichet C, Bloch-Michel E, Roullet E (1999) Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology 52(1):179–81

    PubMed  CAS  Google Scholar 

  8. Bloch-Michel E, Nussenblatt RB (1987) International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 103(2): 234–5

    PubMed  CAS  Google Scholar 

  9. Breger BC, Leopold IH (1966) The incidence of uveitis in multiple sclerosis. Am J Ophthalmol 62(3):540–5

    Google Scholar 

  10. CHAMPS Study Group (2001) Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 132(4):463–71

    Google Scholar 

  11. Constantinescu CS, Lavi E (2000) Anterior uveitis in murine relapsing experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). Curr Eye Res 20(1):71–6

    PubMed  CAS  Google Scholar 

  12. Dhib-Jalbut S (1997) Mechanisms of interferon beta action in multiple sclerosis. Mult Scler 3(6):397–401

    PubMed  CAS  Google Scholar 

  13. Galetta SL (2001) The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study). J Neuroophthalmol 21(4): 292–5

    PubMed  CAS  Google Scholar 

  14. Hu P, Pollard J, Hunt N, Chan-Ling T (1998) Microvascular and cellular responses in the retina of rats with acute experimental allergic encephalomyelitis (EAE). Brain Pathol 8(3):487–98

    PubMed  CAS  Google Scholar 

  15. Hu P, Pollard J, Hunt N, et al. (1998) Microvascular and cellular responses in the optic nerve of rats with acute experimental allergic encephalomyelitis (EAE). Brain Pathol 8(3):475–86

    PubMed  CAS  Google Scholar 

  16. Jacobs LD, Beck RW, Simon JH, et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343(13):898–904

    PubMed  CAS  Google Scholar 

  17. James DG, Friedmann AI, Graham E (1976) Uveitis. A series of 368 patients. Trans Ophthalmol Soc U K 96(1):108–12

    PubMed  CAS  Google Scholar 

  18. Jiang H, Milo R, Swoveland P, et al. (1995) Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells. J Neuroimmunol 61(1): 17–25

    PubMed  Google Scholar 

  19. Lim JI, Tessler HH, Goodwin JA (1991) Anterior granulomatous uveitis in patients with multiple sclerosis. Ophthalmology 98(2):142–5

    PubMed  CAS  Google Scholar 

  20. Malinowski SM, Pulido JS, Folk JC (1993) Long-term visual outcome and complications associated with pars planitis. Ophthalmology 100(6):818–24; discussion 25

    PubMed  CAS  Google Scholar 

  21. Meisler DM, Tomsak RL, Khoury S, et al. (1989) Anterior uveitis and multiple sclerosis. Cleve Clin J Med 56(5):535–8

    PubMed  CAS  Google Scholar 

  22. Minagar A, Long A, Ma T, et al. (2003) Interferon (IFN)-beta1a and IFN-beta1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier. Endothelium 10(6):299–307

    PubMed  CAS  Google Scholar 

  23. Okada AA, Keino H, Fukai T, et al. (1998) Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 6(4):215–26

    PubMed  CAS  Google Scholar 

  24. Optic Neuritis Study Group (1997) The 5-year risk of MS after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Neurology 49(1404–1418)

    Google Scholar 

  25. Porter R (1972) Uveitis in association with multiple sclerosis. Br J Ophthalmol 56(6):478–81

    PubMed  CAS  Google Scholar 

  26. Poser CM, Paty DW, Scheinberg L, et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13(3):227–31

    PubMed  CAS  Google Scholar 

  27. PRISMS-4 (2001) Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56(12):1628–36

    Google Scholar 

  28. PRISMS Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352(9139): 1498–504

    Google Scholar 

  29. Rothova A, Buitenhuis HJ, Meenken C, et al. (1992) Uveitis and systemic disease. Br J Ophthalmol 76(3):137–41

    PubMed  CAS  Google Scholar 

  30. Rucker CW (1945) Sheathing of the retinal veins in multiple sclerosis. JAMA 127:970–3

    Google Scholar 

  31. Satoh J, Paty DW, Kim SU (1995) Differential effects of beta and gamma interferons on expression of major histocompatibility complex antigens and intercellular adhesion molecule-1 in cultured fetal human astrocytes. Neurology 45(2):367–73

    PubMed  CAS  Google Scholar 

  32. Schmidt S, Wessels L, Augustin A, Klockgether T (2001) Patients with multiple sclerosis and concomitant uveitis/periphlebitis retinae are not distinct from those without intraocular inflammation. J Neurol Sci 187(1–2):49–53

    PubMed  CAS  Google Scholar 

  33. Shikishima K, Lee WR, Behan WM, Foulds WS (1993) Uveitis and retinal vasculitis in acute experimental allergic encephalomyelitis in the Lewis rat: an ultrastructural study. Exp Eye Res 56(2):167–75

    PubMed  CAS  Google Scholar 

  34. Stübiger N, Koetter I, Zierhut M (2000) Complete regression of retinal neovascularization after therapy with interferon alfa in Behcet’s disease. Br J Ophthalmol 84(12): 1437–8

    Google Scholar 

  35. Towler HM, Lightman S (2000) Symptomatic intraocular inflammation in multiple sclerosis. Clin Exp Ophthalmol 28(2):97–102

    CAS  Google Scholar 

  36. Verhagen C, Mor F, Cohen IR (1994) T cell immunity to myelin basic protein induces anterior uveitis in Lewis rats. J Neuroimmunol 53(1):65–71

    PubMed  CAS  Google Scholar 

  37. Villarroya H, Klein C, Thillaye-Goldenberg B, Eclancher F (2001) Distribution in ocular structures and optic pathways of immunocompetent and glial cells in an experimental allergic encephalomyelitis (EAE) relapsing model. J Neurosci Res 63(6):525–35

    PubMed  CAS  Google Scholar 

  38. Wakefield D, Jennings A, McCluskey PJ (2000) Intravenous pulse methylprednisolone in the treatment of uveitis associated with multiple sclerosis. Clin Exp Ophthalmol 28(2):103–6

    CAS  Google Scholar 

  39. Yong VW, Chabot S, Stuve O, Williams G (1998) Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 51(3):682–9

    PubMed  CAS  Google Scholar 

  40. Younge BR (1976) Fluorescein angiography and retinal venous sheathing in multiple sclerosis. Can J Ophthalmol 11(1):31–6

    PubMed  CAS  Google Scholar 

  41. Zierhut M, Foster CS (1992) Multiple sclerosis, sarcoidosis and other diseases in patients with pars planitis. Dev Ophthalmol 23:41–7

    PubMed  CAS  Google Scholar 

References

  1. Akova YA, Foster CS (1994) Cataract surgery in patients with sarcoidosis-associated uveitis. Ophthalmology 101(3):473–9

    PubMed  CAS  Google Scholar 

  2. American Thoracic Society (1999) Statement on sarcoidosis. Am J Respir Cri Care Med 160(2):736–755

    Google Scholar 

  3. Augustin AJ, Boker T, Seewald S, et al. (1994) Solitary retinal granuloma as a presenting sign of sarcoidosis. Ger J Ophthalmol 3:71–72

    PubMed  CAS  Google Scholar 

  4. Baarsma GS, La Hey E, Glasius E (1987) The predictive value of serum angiotensin converting enzyme and lysozyme levels in the diagnosis of ocular sarcoidosis. Am J Ophthalmol 104(3):211–7

    PubMed  CAS  Google Scholar 

  5. Baughman RP, Bradley DA, Lower EE (2005) Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 43(1):7–11

    PubMed  CAS  Google Scholar 

  6. Bourcier T, Lumbroso L, Cassoux N (1998) Retinal pigment epithelial detachment: an unusual presentation in ocular sarcoidosis. Br J Ophthalmol 82(5):585

    PubMed  CAS  Google Scholar 

  7. Brazis PW, Stewart M, Lee AG (2004) The uveo-meningeal syndromes. Neurologist 10(4):171–84

    PubMed  Google Scholar 

  8. Campo RV, Aaberg TM (1984) Choroidal granuloma in sarcoidosis. Am J Ophthalmol 97(4):419–27

    PubMed  CAS  Google Scholar 

  9. Castagna I, Salmeri G, Fama F, et al. (1994) Optic nerve granuloma as first sign of systemic sarcoidosis. Ophthalmologica 208(4):230–2

    PubMed  CAS  Google Scholar 

  10. Cheung CM, Durrani OM, Stavrou P (2002) Peripapillary choroidal neovascularisation in sarcoidosis. Ocul Immunol Inflamm 10(1):69–73

    PubMed  CAS  Google Scholar 

  11. Collison JMT, Miller NR, Green WR (1986) Involvement of orbital tissues by sarcoid. Am J Ophthalmol 102:302–307

    PubMed  CAS  Google Scholar 

  12. Constantino T, Digre K, Zimmerman P (2000) Neuro-ophthalmic complications of sarcoidosis. Semin Neurol 20(1): 123–37

    PubMed  CAS  Google Scholar 

  13. Cook BE Jr, Robertson DM (2000) Confluent choroidal infiltrates with sarcoidosis. Retina 29(1):1–7

    Google Scholar 

  14. Cook JR, Brubaker RF, Savell J (1972) Lacrimal sarcoidosis treated with corticosteroids. Arch Ophthalmol 88(5):513–7

    PubMed  CAS  Google Scholar 

  15. Crystal RG, Bitterman PB, Rennard SI, et al. (1984) Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med 310(4):235–44

    PubMed  CAS  Google Scholar 

  16. Di Alberti L, Piattelli A, Favia G, et al. (1997) Human herpesvirus 8 variants in sarcoid tissues. Lancet 350:1655–1661

    PubMed  Google Scholar 

  17. Dick DJ, Newman PK, Richardson J, et al. (1988) Acute posterior multifocal placoid pigment epitheliopathy and sarcoidosis. Br J Ophthalmol. 72(1):74–7

    PubMed  CAS  Google Scholar 

  18. Dios E, Saornil MA, Herreras JM (2001) Conjunctival biopsy in the diagnosis of ocular sarcoidosis. Ocul Immunol Inflamm 9(1):59–64

    PubMed  CAS  Google Scholar 

  19. Dodds EM, Lowder CY, Barnhorst DA (1995) Posterior scleritis with annular ciliochoroidal detachment. Am J Ophthalmol 120(5):677–9

    PubMed  CAS  Google Scholar 

  20. Duker JS, Brown GC, McNamara JA (1988) Proliferative sarcoid retinopathy. Ophthalmology 95(12):1680–6

    PubMed  CAS  Google Scholar 

  21. Dursun D, Akova YA, Bilezikci B (2004) Scleritis associated with sarcoidosis. Ocul Immunol Inflamm 12(2):143–8

    PubMed  Google Scholar 

  22. Faller M, Purohit A, Kennel N, et al. (1995) Systemic sarcoidosis initially presenting as an orbital tumour. Eur Respir J 8(3):474–6

    PubMed  CAS  Google Scholar 

  23. Franchescetti A, Babel J (1949) La chorio-retinie en ‘taches de bougie’, manifestation de la maladie de Besnier-Boeck. Ophthalmologica 118:701–710

    Google Scholar 

  24. Furuya K, Yamaguchi E, Itoh A, et al. (1996) Deletion polymorphism in the angiotensin I converting enzyme (ACE) gene as a genetic risk factor for sarcoidosis. Thorax 51(8): 777–80

    PubMed  CAS  Google Scholar 

  25. Geggel HS, Mensher JH (1989) Cicatricial conjunctivitis in sarcoidosis: recognition and treatment. Ann Ophthalmol 21(3):92–4

    PubMed  CAS  Google Scholar 

  26. Graham EM, Stanford MR, Shilling JS, et al. (1987) Neovascularisation associated with posterior uveitis. Br J Ophthalmol 71(11):826–33

    PubMed  CAS  Google Scholar 

  27. Hall JG, Cohen KL (1995) Sarcoidosis of the eyelid skin. Am J Ophthalmol 119:100–101

    PubMed  CAS  Google Scholar 

  28. Hamanaka T, Takei A, Takemura T (2002) Pathological study of cases with secondary open-angle glaucoma due to sarcoidosis. Am J Ophthalmol 134(1):17–26

    PubMed  Google Scholar 

  29. Hunninghake GW, Crystal RG (1981) Pulmonary sarcoidosis: a disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med 305(8): 429–34

    PubMed  CAS  Google Scholar 

  30. Hunter DG, Foster CS (1994) Ocular manifestations of sarcoidosis. In: Albert DM, Jakobeiec FA (eds) Principles and practice of ophthalmology. Saunders, Philadelphia, pp 443–450

    Google Scholar 

  31. Inagaki M, Harada T, Kiribuchi T, et al. (1996) Subfoveal choroidal neovascularization in uveitis. Ophthalmologica 210(4):229–33

    PubMed  CAS  Google Scholar 

  32. Iwai K, Sekiguti M, Hosoda Y, et al. (1994) Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 11:26–31

    PubMed  CAS  Google Scholar 

  33. James DG, Kendig EL, Jr (1988) Childhood sarcoidosis. Sarcoidosis 5:57–59

    PubMed  CAS  Google Scholar 

  34. James DG, Neville E, Siltzbach LE (1976) A worldwide review of sarcoidosis. Ann N Y Acad Sci 278:321–34

    PubMed  CAS  Google Scholar 

  35. James GD, Hosada Y (1994) Epidemiology. In: Sarcoidosis and other granulomatous disorders. Marcel Dekker, New York, pp 729–743

    Google Scholar 

  36. Jurowski P, Gos R, Kunert-Radek J (2002) Long acting analogue of somatostatin (Octreotide) for treatment of patients with neurochorioretinitis due to ocular sarcoidosis who failed corticosteroids therapy. Klin Oczna 104(3–4):266–9

    PubMed  Google Scholar 

  37. Kuboshiro T, Yoshioka H (1988) Birdshot retinochoroidopathy-a possible relationship to ocular sarcoidosis. Kurume Med J 35(4):193–9

    PubMed  CAS  Google Scholar 

  38. Lardenoye CW, Van der Lelij A, de Loos WS, et al. (1997) Peripheral multifocal chorioretinitis: a distinct clinical entity? Ophthalmology 104(11):1820–6

    PubMed  CAS  Google Scholar 

  39. Liggett PE (1986) Ocular sarcoidosis. Clin Dermatol 4(4): 129–35

    PubMed  CAS  Google Scholar 

  40. Lobo A, Barton K, Minassian D, et al. (2003) Visual loss in sarcoid-related uveitis. Clin Exp Ophthalmol 31(4):310–6

    Google Scholar 

  41. Machida S, Tanaka M, Murai K (2004) Choroidal circulatory disturbance in ocular sarcoidosis without the appearance of retinal lesions or loss of visual function. Jpn J Ophthalmol 48(4):392–6

    PubMed  Google Scholar 

  42. Martin DF, Chan CC, de Smet MD, et al. (1993) The role of chorioretinal biopsy in the management of posterior uveitis. Ophthalmology 100(5):705–14

    PubMed  CAS  Google Scholar 

  43. Maycock RL, Bertrand P, Morrison CE, et al. (1963) Manifestations of sarcoidosis. Analysis of 145 patients, with a review of nine series selected from the literature. Am J Med 35:67–89

    Google Scholar 

  44. McGrath DS, Goh N, Foley PJ, et al. (2001) Sarcoidosis genes and microbes: soil or seed. Sarcoidosis Vasc Diffuse Lung Dis 18(2):149–64

    PubMed  CAS  Google Scholar 

  45. Niimi T, Tomita H, Sato S, et al. (1999) Vitamin D receptor gene polymorphism in patients with sarcoidosis. Am J Respir Crit Care Med 160:1107–1109

    PubMed  CAS  Google Scholar 

  46. Obenauf CD, Shaw HE, Sydnor CF, et al. (1978) Sarcoidosis and its ophthalmic manifestations. Am J Ophthalmol 86: 648–655

    PubMed  CAS  Google Scholar 

  47. Okhravi N, Lightman SL, Towler HM (1999) Assessment of visual outcome after cataract surgery in patients with uveitis. Ophthalmology 106(4):710–22

    PubMed  CAS  Google Scholar 

  48. Perez RL, Rivera-Marrero CA, Roman J (2003) Pulmonary granulomatous inflammation: From sarcoidosis to tuberculosis. Semin Respir Infect 18(1):23–32

    PubMed  Google Scholar 

  49. Pietinalho A, Ohmichi M, Löfroos AB, et al. (2000) The prognosis of pulmonary sarcoidosis in Finland and Hokkaido, Japan. A comparative five year study of biopsy-proven cases. Sarcoidosis Vasc Diffuse Lung Dis 17:158–166

    PubMed  CAS  Google Scholar 

  50. Power WJ, Neves RA, Rodriguez A, et al. (1995) The value of combined serum angiotensin-converting enzyme and gallium scan in diagnosing ocular sarcoidosis. Ophthalmology 102(12):2007–11

    PubMed  CAS  Google Scholar 

  51. Rothova A (2000) Ocular involvement in sarcoidosis. Br J Ophthalmol 84:110–116

    PubMed  CAS  Google Scholar 

  52. Rothova A, Alberts C, Glasius E, et al. (1989) Risk factors for ocular sarcoidosis. Doc Ophthalmol 72:287–296

    PubMed  CAS  Google Scholar 

  53. Rothova A, Lardenoye C (1998) Arterial macroaneurysms in peripheral multifocal chorioretinitis associated with sarcoidosis. Ophthalmology 105(8):1393–7

    PubMed  CAS  Google Scholar 

  54. Rybicki BA, Maliarik MJ, Major M, et al. (1997) Genetics of sarcoidosis. Clin Chest Med 18:707–717

    PubMed  CAS  Google Scholar 

  55. Rybicki BA, Maliarik MJ, Poisson LM, et al. (1997) Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 145(3): 234–41

    PubMed  CAS  Google Scholar 

  56. Sekiya M, Ohwada A, Miura K, et al. (2003) Serum vascular endothelial growth factor as a possible prognostic indicator in sarcoidosis. Lung 181(5):259–65

    PubMed  CAS  Google Scholar 

  57. Sharma OP (1972) Cutaneous sarcoidosis: clinical features and management. Chest 61(4):320–5

    PubMed  CAS  Google Scholar 

  58. Sharma OP (1996) Vitamin D, calcium, and sarcoidosis. Chest 109:535–539

    PubMed  CAS  Google Scholar 

  59. Sharma OP (1997) Cardiac and neurologic dysfunction in sarcoidosis. Clin Chest Med 18(4):813–25

    PubMed  CAS  Google Scholar 

  60. Sherman JL, Stern BJ (1990) Sarcoidosis of the CNS: comparison of unenhanced and enhanced MR images. AJNR Am J Neuroradiol 11(5):915–23

    PubMed  CAS  Google Scholar 

  61. Shetty AK, Zganjar BE, Ellis GS, Jr, et al. (1999) Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. J Pediatr Ophthalmol Strabismus 36(3):125–8

    PubMed  CAS  Google Scholar 

  62. Siltzbach LE, Geraint James D, Neville E, et al. (1974) Course and prognosis of sarcoidosis around the world. Am J Med 57:847–852

    Google Scholar 

  63. Somoskovi A, Zissel G, Seitzer U (1999) Polymorphisms at position −308 in the promoter region of the TNF-alpha and in the first intron of the TNF-beta genes and spontaneous and lipopolysaccharide-induced TNF-alpha release in sarcoidosis. Cytokine 11(11):882–7

    PubMed  CAS  Google Scholar 

  64. Sonoda KH, Enaida H, Ueno A, et al. (2003) Pars plana vitrectomy assisted by triamcinolone acetonide for refractory uveitis: a case series study. Br J Ophthalmol 87(8):1010–4

    PubMed  Google Scholar 

  65. Stanbury RM, Graham EM, Murray PI (1995) Sarcoidosis. Int Ophthalmol Clin 35(3):123–37

    PubMed  CAS  Google Scholar 

  66. Stavrou P, Linton S, Young DW, et al. (1997) Clinical diagnosis of ocular sarcoidosis. Eye 11(3):365–70

    PubMed  Google Scholar 

  67. Stern BJ, Krumholz A, Johns C, et al. (1985) Sarcoidosis and its neurological manifestations. Arch Neurol 42(9):909–17

    PubMed  CAS  Google Scholar 

  68. Tahmoush AJ, Amir MS, Connor WW, Farry JK, Didato S, Ulhoa-Cintra A, Vasas JM, Schwartzman RJ, Israel HL, Patrick H (2002) CSF-ACE activity in probable CNS neurosarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 19(3):191–7

    PubMed  Google Scholar 

  69. Takada K, Ina Y, Noda M, et al. (1993) The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis. J Clin Epidemiol 46(4):359–66

    PubMed  CAS  Google Scholar 

  70. Verleden GM, du Bois RM, Bouros D, et al. (2001) Genetic predisposition and pathogenetic mechanisms of interstitial lung diseases of unknown origin. Eur Respir J 18:Suppl 32:17s–29s

    Google Scholar 

  71. Watts PO, Mantry S, Austin M (2000) Serous retinal detachment at the macula in sarcoidosis. Am J Ophthalmol 129(2):262–4

    PubMed  CAS  Google Scholar 

  72. Winterbauer RH, Lammert J, Selland M, et al. (1993) Bronchoalveolar lavage cell populations in the diagnosis of sarcoidosis. Chest 104(2):352–61

    PubMed  CAS  Google Scholar 

  73. Wolfensberger TJ, Herbort CP (1999) Indocyanine green angiographic features in ocular sarcoidosis. Ophthalmology 106(2):285–9

    PubMed  CAS  Google Scholar 

  74. Yoshikawa K, Kotake S, Ichiishi A, et al. (1995) Posterior sub-Tenon injections of repository corticosteroids in uveitis patients with cystoid macular edema. Jpn J Ophthalmol 39(1):71–6

    PubMed  CAS  Google Scholar 

References

  1. Acheson JF, Cockerell OC, Bentley CR, Sanders MD (1993) Churg-Strauss vasculitis presenting with severe visual loss due to bilateral sequential optic neuropathy. Br J Ophthalmol 77:118–119

    PubMed  CAS  Google Scholar 

  2. Alberts AR, Lasonde R, Ackerman KR, Chartash EK, Susin M, Furie RA (1994) Reversible monocular blindness complicating Churg-Strauss syndrome. J Rheumatol 21:363–365

    PubMed  CAS  Google Scholar 

  3. Baranger TA, Audrain MA, Castagne A, Barrier JH, Esnault VL (1994) Absence of antineutrophil cytoplasmic antibodies in giant cell arteritis. J Rheumatol 21:871–873

    PubMed  CAS  Google Scholar 

  4. Bosch-Gil JA, Falga-Tirado C, Simeon-Aznar CP, Orriols-Martinez R (1995) Churg-Strauss syndrome with inflammatory orbital pseudotumour. Br J Rheumatol 34:485–486

    PubMed  CAS  Google Scholar 

  5. Bullen CL, Liesegang TJ, McDonald TJ, DeRemee RA (1983) Ocular complications of Wegener’s granulomatosis. Ophthalmology 90:279–290

    PubMed  CAS  Google Scholar 

  6. Chang TS et al (1995) Idiopathic retinal vasculitis, aneurysms, and neuro-retinitis. Retinal Vasculitis Study. Ophthalmology 102:1089–1097

    PubMed  CAS  Google Scholar 

  7. Costello F, Gilberg S, Karsh J, Burns B, Leonard B (2005) Bilateral simultaneous central retinal artery occlusions in Wegener granulomatosis. J Neuroophthalmol 25:29–32

    PubMed  Google Scholar 

  8. Csernok E (2003) Anti-neutrophil cytoplasmic antibodies and pathogenesis of small vessel vasculitides. Autoimmun Rev 2:158–164

    PubMed  CAS  Google Scholar 

  9. Dagi LR, Currie J (1985) Branch retinal artery occlusion in the Churg-Strauss syndrome. J Clin Neuroophthalmol 5:229–237

    PubMed  CAS  Google Scholar 

  10. De Groot K, Adu D, Savage CO (2001) The value of pulse cyclophosphamide in ANCA-associated vasculitis: metaanalysis and critical review. Nephrol Dial Transplant 16: 2018–2027

    PubMed  Google Scholar 

  11. DeRemee RA (1994) Sarcoidosis and Wegener’s granulomatosis: a comparative analysis. Sarcoidosis 11:7–18

    PubMed  CAS  Google Scholar 

  12. Font RL, Mehta RS, Streusand SB, O’Boyle TE, Kretzer FL (1983) Bilateral retinal ischemia in Kawasaki disease. Postmortem findings and electron microscopic observations. Ophthalmology 90:569–577

    PubMed  CAS  Google Scholar 

  13. Goek ON, Stone JH (2005) Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies. Curr Opin Rheumatol. 17:257–264

    PubMed  CAS  Google Scholar 

  14. Googe JM Jr, Brady SE, Argyle JC, Apple DJ, Gooch WM III (1985) Choroiditis in infantile periarteritis nodosa. Arch Ophthalmol 103:81–83

    PubMed  Google Scholar 

  15. Guillevin L et al. (1996) Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 75:17–28

    PubMed  CAS  Google Scholar 

  16. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P (1999) Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 78:26–37

    PubMed  CAS  Google Scholar 

  17. Haynes BF, Fishman ML, Fauci AS, Wolff SM (1977) The ocular manifestations of Wegener’s granulomatosis. Fifteen years experience and review of the literature. Am J Med 63:131–141

    PubMed  CAS  Google Scholar 

  18. Hellmich B, Ehlers S, Csernok E, Gross WL (2003) Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 21:S69–S77

    PubMed  CAS  Google Scholar 

  19. Hsu CT, Kerrison JB, Miller NR, Goldberg MF (2001) Choroidal infarction, anterior ischemic optic neuropathy, and central retinal artery occlusion from polyarteritis nodosa. Retina 21:348–351

    PubMed  CAS  Google Scholar 

  20. Hunder GG et al (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 33:1065–1067

    PubMed  CAS  Google Scholar 

  21. Ibanez BF, Bonal-Pitz P, Fernandez-Torres C, Pulido F, de la RL (1983) A case of Churg-Strauss syndrome with ocular involvement. Med Clin(Barc) 81:769–771

    Google Scholar 

  22. Jennette JC et al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37:187–192

    PubMed  CAS  Google Scholar 

  23. Keogh KA, Specks U (2003) Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 115:284–290

    PubMed  CAS  Google Scholar 

  24. Kielar RA (1976) Exudative retinal detachment and scleritis in polyarteritis. Am J Ophthalmol 82:694–698

    PubMed  CAS  Google Scholar 

  25. Langford CA (2003) Treatment of ANCA-associated vasculitis. N Engl J Med 349:3–4

    PubMed  Google Scholar 

  26. Lhote F, Cohen P, Guillevin L (1998) Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Lupus 7:238–258

    PubMed  CAS  Google Scholar 

  27. Lie JT (1997) Wegener’s granulomatosis: histological documentation of common and uncommon manifestations in 216 patients. Vasa 26:261–270

    PubMed  CAS  Google Scholar 

  28. Lynch JM, Barrett TL (2004) Collagenolytic (necrobiotic) granulomas, part 1. The “blue” granulomas. J Cutan Pathol 31:353–361

    PubMed  Google Scholar 

  29. Masi AT et al (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33:1094–1100

    PubMed  CAS  Google Scholar 

  30. Matteson EL, Gold KN, Bloch DA, Hunder GG (1996) Long-term survival of patients with Wegener’s granulomatosis from the American College of Rheumatology Wegener’s Granulomatosis Classification Criteria Cohort. Am J Med 101:129–134

    PubMed  CAS  Google Scholar 

  31. Newman NM, Hoyt WF, Spencer WH (1974) Macula-sparing monocular blackouts. Clinical and pathologic investigations of intermittent choroidal vascular insufficiency in a case of periarteritis nodosa. Arch Ophthalmol 91:367–370

    PubMed  CAS  Google Scholar 

  32. Rosen ES (1968) The retinopathy in polyarteritis nodosa. Br J Ophthalmol 52:903–906

    PubMed  CAS  Google Scholar 

  33. Schmidt D, Lagreze W, Vaith P (2001) Ophthalmoscopic findings in 3 patients with panarteritis nodosa and review of the literature. Klin Monatsbl Augenheilkd 218:44–50

    PubMed  CAS  Google Scholar 

  34. Seo P et al (2005) Damage caused by Wegener’s granulomatosis and its treatment: prospective data from the Wegener’s Granulomatosis Etanercept Trial (WGET). Arthritis Rheum 52:2168–2178

    PubMed  CAS  Google Scholar 

  35. Stefani FH, Brandt F, Pielsticker K (1978) Periarteritis nodosa and thrombotic thrombocytopenic purpura with serous retinal detachment in siblings. Br J Ophthalmol 62:402–407

    PubMed  CAS  Google Scholar 

  36. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG (1996) Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener’s granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335:16–20

    PubMed  CAS  Google Scholar 

  37. Takanashi T, Uchida S, Arita M, Okada M, Kashii S (2001) Orbital inflammatory pseudotumor and ischemic vasculitis in Churg-Strauss syndrome: report of two cases and review of the literature. Ophthalmology 108:1129–1133

    PubMed  CAS  Google Scholar 

  38. The Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group (2005) Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 352:351–361

    Google Scholar 

  39. Venkatesh P, Chawla R, Tewari HK (2003) Hemiretinal vein occlusion in Wegener’s granulomatosis. Eur J Ophthalmol 13:722–725

    PubMed  CAS  Google Scholar 

  40. Vitali C, Genovesi-Ebert F, Romani A, Jeracitano G, Nardi M (1996) Ophthalmological and neuro-ophthalmological involvement in Churg-Strauss syndrome: a case report. Graefes Arch Clin Exp Ophthalmol 234:404–408

    PubMed  CAS  Google Scholar 

  41. Yi ES, Colby TV (2001) Wegener’s granulomatosis. Semin Diagn Pathol 18:34–46

    PubMed  CAS  Google Scholar 

References

  1. Akpek EK, Jabs DA, Tessler HH, Joondeph BS, Foster CS (2002) Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology 109:1508–1513

    Google Scholar 

  2. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche TJ, Marshall J (2001) Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 108:765–772

    PubMed  CAS  Google Scholar 

  3. Becker MD, Rosenbaum JT (2000) Current and future trends in the use of immuno-suppressive agents in patients with uveitis. Curr Opin Ophthalmol 11:472–477

    PubMed  CAS  Google Scholar 

  4. Berk PA, Goldberg JD, Silverman MN, Weinfeld A, Donovan PB, Ellis JT, Landaw SA, Laszlo J, Najean Y, Pisciotta AV, Wasserman LR (1981) Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 304:441–447

    PubMed  CAS  Google Scholar 

  5. Carnahan MC, Goldstein DA (2000) Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 11:478–483

    PubMed  CAS  Google Scholar 

  6. Ciulla TA, Walker JD, Fong DS, Criswell MH (2004) Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol 15:211–220

    PubMed  Google Scholar 

  7. Cunningham ET (2002) Diagnosis and management of acute anterior uveitis. In Focal Points, AAO

    Google Scholar 

  8. Cunningham ET (2000) Uveitis in children. Ocul Immunol Inflamm 8:251–261

    PubMed  Google Scholar 

  9. Eriksson P (2005) Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 257:540–548

    PubMed  CAS  Google Scholar 

  10. Foster CS, Baer JC, Raizman MB (1991) Therapeutic responses to systemic immunosuppressive chemotherapy agents in patients with Behcet’s syndrome affecting eyes. In: O’Duffy JD, Kokmen E (eds) Behcet’s disease: basic and clinical aspects. Dekker, New York, pp 581–588

    Google Scholar 

  11. Foster CS, Vitale AT (2002) Immunosuppressive chemotherapy. In: Foster CS, Vitale AT (eds) Diagnosis and treatment of uveitis. Saunders, Philadelphia, pp 141–214

    Google Scholar 

  12. Foster CS (2003) Diagnosis and treatment of juvenile idiopathic arthritis associated uveitis. Curr Opin Ophthalmol 14:395–398

    PubMed  Google Scholar 

  13. Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, Vredeveld CM (2003) Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 121:437–440

    PubMed  CAS  Google Scholar 

  14. Goldstein DA, Fontanilla FA, Kaul S, Sahin O, Tessler HH (2002) Long-term follow-up of patients treated with short-term, high dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology109:370–377

    PubMed  Google Scholar 

  15. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, Nussenblatt RB, Stiehm ER, Tessler H, Van Gelder RN, Whitcup SM, Yocum D (2000) Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130:492–513

    PubMed  CAS  Google Scholar 

  16. Kilmartin DJ, Forrester JV, Dick AD (1998) Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol 82:737–742.

    PubMed  CAS  Google Scholar 

  17. Kiss S, Letko E, Qamruddin S, Baltatzis S, Foster CS (2003) Long-term progression, prognosis, and treatment of patients with recurrent ocular manifestations of Reiter’s syndrome. Ophthalmology 110:1764–1769

    PubMed  Google Scholar 

  18. Koizumi K, Poulaki V, Doehmen S, Welsandt G, Radetzky S, Lappas A, Kociok N, Kirchhof B, Joussen AM (2003) Contribution of TNF-alpha to leukocytes adhesion, vascular leakage, and apoptotic cell death in endotoxin-induced uveitis in vivo. Invest Ophthalmol Vis Sci 44:2184–2191

    PubMed  Google Scholar 

  19. Kotter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Gunaydin I, Grimbacher B, Blaschke S, Meyer-Riemann W, Peter HH, Stubiger N (2003) Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423–431

    PubMed  CAS  Google Scholar 

  20. McGhee CN, Dean S, Danesh-Meyer H (2002) Locally administered ocular corticosteroids: benefits and risks. Drug Saf 25:33–55

    PubMed  CAS  Google Scholar 

  21. Miserocchi E, Baltatzis S, Ekong A, Roque M, Foster CS (2002) Efficacy and safety of chlorambucil in intractable noninfectious uveitis. Ophthalmology 109:137–142

    PubMed  Google Scholar 

  22. Mochizuki M, Masuda K, Tuyoshi S, Ito K, Kogure M, Sugino N, Usui M, Mizushima Y, Ohno S, Inaba G (1993) A clinical trial of FK 506 in refractory uveitis. Am J Ophthalmol 115:763–769

    PubMed  CAS  Google Scholar 

  23. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D (2004) Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 111:352–356

    PubMed  Google Scholar 

  24. Newell FW, Krill AE (1967) Treatment of uveitis with azathioprine. Trans Ophthalmol Soc 87:499–511

    CAS  Google Scholar 

  25. Nussenblatt RB, Palestine AG, Rook AH, Scher I, Wacker WB, Gery I (1983) Treatment of intraocular inflammation with cyclosporine A. Lancet 1:235–238

    Google Scholar 

  26. Nussenblatt RB, Palestine AG, Chan CC (1983) Cyclosporine A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 96:275–282

    PubMed  CAS  Google Scholar 

  27. Nussenblatt RB, Thompson DJ, Li Z, Chan CC, Peterson JS, Robinson RR, Shames RS, Nagarajan S, Tang MT, Mailman M, Velez G, Roy C, Levy-Clarke GA, Suhler EB, Djalilian A, Sen HN, Al-Khatib S, Ursea R, Srivastava S, Bamji A, Mellow S, Sran P, Waldmann TA, Buggage RR (2003) Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 21:283–293

    PubMed  CAS  Google Scholar 

  28. Ozdal PC, Ortac S, Taskintuna I, Firat E (2002) Long-term therapy with low dose cyclosporine A in ocular Behcet’s disease. Doc Ophthalmol 105:301–312

    PubMed  Google Scholar 

  29. Palestine AG, Nussenblatt RB, Chan CC (1985) Cyclosporine penetration into the anterior chamber and cerebrospinal fluid. Am J Ophthalmol 99:210–211

    PubMed  CAS  Google Scholar 

  30. Papaliodis GN, Chu D, Foster CS (2003) Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 110:786–789

    PubMed  Google Scholar 

  31. Perez-Guijo V, Santos-Lacomba M, Sanchez-Hernandez M, Castro-Villegas Mdel C, Gallardo-Galera JM, Collantes-Estevez E (2004) Tumor necrosis factor-alpha levels in aqueous humor and serum from patients with uveitis: the involvement of HLA-B27. Curr Med Res Opin 20: 155–157

    Google Scholar 

  32. Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, Gallagher K, Stout T (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 45:252–257

    Google Scholar 

  33. Rothova A (2002) Corticosteroids in uveitis. Ophthalmol Clin North Am 15:389–394

    PubMed  Google Scholar 

  34. Samson CM, Waheed N, Baltatzis S, Foster CS (2001) Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 108:1134–1139

    PubMed  CAS  Google Scholar 

  35. Sfikakis PP, Theodossiadia PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet 358:295–296

    PubMed  CAS  Google Scholar 

  36. Shetty AK, Zganjar BE, Ellis GS, Ludwig IH, Gedalia A (1998) Low-dose methotrexate in the treatment of severe juvenile rheumatoid arthritis. J Pediatr 133:266–268

    Google Scholar 

  37. Solomon SD, Cunningham ET (2000) Use of corticosteroids and noncorticosteroid immunosuppressive agents in patients with uveitis. Compr Ophthalmol Update 1:273–286

    Google Scholar 

  38. Suttorp-Schulten MSA, Rothova A (1996) The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol 80:844–848

    PubMed  CAS  Google Scholar 

  39. Thall EH (2003) Dosage of intravitreal triamcinolone. Am J Ophthalmol 136:1192

    PubMed  Google Scholar 

  40. Walton RC, Nussenblatt RB, Whitcup SM (1998) Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology 105:2028–2034

    PubMed  CAS  Google Scholar 

  41. Wechsler B, Bodaghi B, Huong DL, Fardeau C, Amoura Z, Cassoux N, Piette JC, LeHoang P (2000) Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet’s disease. Ocul Immunol Inflamm 8:293–301

    PubMed  CAS  Google Scholar 

  42. Yoshida A, Kawshima H, Motoyama Y, Shibui H, Kaburaki T, Shimizu K, Ando K, Hijikata K, Izawa Y, Hayashi K, Numaga J, Fujino Y, Masuda K, Araie M (2004) Comparison of patients with Behcet’s disease in the 1980’s and 1990’s. Ophthalmology 111:810–815

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gadkari Eye Center, Opp Karve Road, Telephone Exchange, Nal Stop, Pune, 411004, Pune, Maharashtra, India

    Salil Gadkari MS, FRCS, MRCOpth

  2. Casey Eye Institute, Oregon Health & Science University, 3375 SW Terwilliger Blvd., Portland, OR, 97239-4146, USA

    James T. Rosenbaum MD

  3. Department of Ophthalmology, University of Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany

    Friederike Mackensen MD, Matthias D. Becker MD, PhD, FEBO, Ute Wiehler MD & Daniel W. Miller MD

  4. Department of Ophthalmology, University of Tübingen, Schleichstr. 12-16, 72076, Tübingen, Germany

    Manfred Zierhut MD, Nicole Stübiger MD & Christoph Deuter MD

  5. Department of Internal Medicine, University of Tübingen, Ottfried-Müller-Str. 10, 72076, Tübingen, Germany

    Ina Kötter MD

  6. Department of Clinical Ophthalmology, Institute of Ophthalmology, Moorfields Eye Hospital London, City Road, London, EC1V 2PD, UK

    Sobha Sivaprasad MS, DNB, FRCS, Narciss Okhravi BSc, FRCOphth, PhD & Susan Lightman FRCP, FRCOphth, PhD

  7. Bascom Palmer Eye Institute, 900 N.W. 17th Street, Miami, FL, 33136, USA

    Janet L. Davis MD

  8. Yale Eye Center, 330 Cedar Street, P.O. Box 208061, New Haven, CT, 06520-8061, USA

    John J. Huang MD

  9. Massachusetts Eye Research and Surgery Institute, 5 Cambridge Center, 8th Floor, Cambridge, MA, 02142, USA

    C. Stephen Foster MD, PhD, FACS, FACR

Authors
  1. Salil Gadkari MS, FRCS, MRCOpth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James T. Rosenbaum MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Friederike Mackensen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Manfred Zierhut MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nicole Stübiger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ina Kötter MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christoph Deuter MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Matthias D. Becker MD, PhD, FEBO
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ute Wiehler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Daniel W. Miller MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Sobha Sivaprasad MS, DNB, FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Narciss Okhravi BSc, FRCOphth, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Susan Lightman FRCP, FRCOphth, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Janet L. Davis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. John J. Huang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. C. Stephen Foster MD, PhD, FACS, FACR
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Ophthalmology, University of Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Germany

    Antonia M. Joussen MD, PhD (Professor of Ophthalmology) (Professor of Ophthalmology)

  2. Department of Ophthalmology, Penn State College of Medicine, 500 University, Drive Box 850, Hershey, PA, 17033, USA

    Thomas W. Gardner MD, MS (Professor of Ophthalmology) (Professor of Ophthalmology)

  3. Department of Vitreoretinal Surgery, Center for Ophthalmology, University of Cologne, Joseph-Stelzmann-Straße 9, 50931, Cologne, Germany

    Bernd Kirchhof MD (Professor of Ophthalmology) (Professor of Ophthalmology)

  4. Doheny Eye Institute, University of Southern California, 1450 San Pablo Street, Los Angeles, CA, 90033, USA

    Stephen J. Ryan MD (Professor of Ophthalmology) (Professor of Ophthalmology)

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Gadkari, S. et al. (2007). Inflammatory Vascular Disease. In: Joussen, A.M., Gardner, T.W., Kirchhof, B., Ryan, S.J. (eds) Retinal Vascular Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-29542-6_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-29542-6_25

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-29541-9

  • Online ISBN: 978-3-540-29542-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation